Terkko Navigator / -/ Feeds / "eur urol "

Re: Ekaterina Laukhtina, Shahrokh F. Shariat. Phase II Study of Gemcitabine and Split-dose Cisplatin plus Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients with Muscle-invasive Bladder Cancer. Eur Urol. In press. https://doi.

Re: Luke Harper, T. Blanc, M. Peycelon, et al. Circumcision and Risk of Febrile Urinary Tract Infection in Boys with Posterior Urethral Valves: Result of the CIRCUP Randomized Trial. Eur Urol. 2022;81:64–72

Reply from Authors re: Peter C. Albertsen. The Treatment Paradigm Shifts Again on Prostate Cancer. Eur Urol. In press. doi: 10.1016/j.eururo.2008.09.014.

Reply from Authors re: Giuseppe Morgia. Does the Use of Silodosin to Treat Benign Prostatic Hyperplasia Really Offer Something New? Eur Urol. In press. doi:10.1016/j.eururo.2010.11.023.

Reply from Authors re: Guido Barbagli, Salvatore Sansalone, Massimo Lazzeri. Oral Mucosa and Urethroplasty: It's Time to Change. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2012.07.042: Oral Mucosa as a Reservoir of Human Papillomavirus: I

Reply from Authors re: Guido Barbagli, Salvatore Sansalone, Massimo Lazzeri. Oral Mucosa and Urethroplasty: It's Time to Change. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2012.07.042: Oral Mucosa as a Reservoir of Human Papillomavirus: I

Reply from Authors re: Nicolas Mottet Intermittent Androgen Deprivation in Prostate Cancer: Is Everything So Clear? Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2012.08.004: Intermittent Androgen Deprivation in Advanced Prostate Cancer: An

Reply from Authors re: Jonathan Bergman, Mark S. Litwin. The Henderson-Hasselbalch Equation for Urologists. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2012.12.021: Health-related Quality-of-life Scores from the Finnish Trial of Screening

Reply from Authors re: Behfar Ehdaie, Karim A. Touijer. 5-Alpha Reductase Inhibitors in Prostate Cancer: From Clinical Trials to Clinical Practice. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2012.12.035: 5-Alpha Reductase Inhibitors in Pr

Reply from Authors re: Jonathan Bergman, Mark S. Litwin. The Henderson-Hasselbalch Equation for Urologists. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2012.12.021: Health-related Quality-of-life Scores from the Finnish Trial of Screening

Re: Fatemeh Seyednasrollah, Mehrad Mahmoudian, Liisa Rautakorpi, et al. How Reliable are Trial-based Prognostic Models in Real-world Patients with Metastatic Castration-resistant Prostate Cancer? Eur Urol. 2017;71:838-40.

Re: Fatemeh Seyednasrollah, Mehrad Mahmoudian, Liisa Rautakorpi, et al. How Reliable are Trial-based Prognostic Models in Real-world Patients with Metastatic Castration-resistant Prostate Cancer? Eur Urol. 2017;71:838-40.

Corrigendum re "Docetaxel Versus Surveillance After Radical Radiotherapy for Intermediate- or High-risk Prostate Cancer-Results from the Prospective, Randomised, Open-label Phase III SPCG-13 Trial" [Eur Urol 2019;76:823-30]

Re: Fatemeh Seyednasrollah, Mehrad Mahmoudian, Liisa Rautakorpi, et al. How Reliable are Trial-based Prognostic Models in Real-world Patients with Metastatic Castration-resistant Prostate Cancer? Eur Urol. 2017;71:838-40

Reply to Laurence Klotz’s Letter to the Editor re: Jeremy Yeun-Chun Teoh, Daniele Castellani, Claudia Mercader, et al. A Quantitative Analysis Investigating the Prevalence of “Manels” in Major Urology Meetings. Eur Urol 2021;80:442–9. Eur Urol 2021;8

Reply to Anirban P. Mitra, Tanner Miest, and Colin P.N. Dinney’s Words of Wisdom re: Genomic Predictors of Good Outcome, Recurrence, or Progression in High-Grade T1 Non-Muscle-Invasive Bladder Cancer. Eur Urol. In press. https://doi.org/10.1016/j.eur

Corrigendum re “Docetaxel Versus Surveillance After Radical Radiotherapy for Intermediate- or High-risk Prostate Cancer—Results from the Prospective, Randomised, Open-label Phase III SPCG-13 Trial” [Eur Urol 2019;76:823–30]

Re: Marcus J. Drake, Amanda L. Lewis, Grace J. Young, et al. Diagnostic Assessment of Lower Urinary Tract Symptoms in Men Considering Prostate Surgery: A Noninferiority Randomised Controlled Trial of Urodynamics in 26 Hospitals. Eur Urol. In press. h

Re: Kathrin Meisterhofer, Sereina Herzog, Karin A. Strini, Luca Sebastianelli, Ricarda Bauer, Orietta Dalpiaz. Male Slings for Postprostatectomy Incontinence: A Systematic Review and Meta-analysis. Eur Urol Focus 2020;6:575–92

Re: Hiten D. Patel, Farzana A. Faisal, Bruce J. Trock, et al. Effect of Pharmacologic Prophylaxis on Venous Thromboembolism After Radical Prostatectomy: The PREVENTER Randomized Clinical Trial. Eur Urol 2020;78:360–8

Corrigendum to “A standard operating technique to facilitate early return of urinary continence after robotic prostatectomy outcomes of a consensus meeting of experts with experience of over 30,000 cases” [Eur Urol Suppl 2017;16;e2301–2]

Re: Hiten D. Patel, Farzana A. Faisal, Bruce J. Trock, et al. Effect of Pharmacologic Prophylaxis on Venous Thromboembolism After Radical Prostatectomy: The PREVENTER Randomized Clinical Trial. Eur Urol 2020;78:360–8

Re: Alfonso Gómez de Liaño Lista, Nick van Dijk, Guillermo de Velasco Oria de Rueda, et al. Clinical Outcome After Progressing to Frontline and Second-line Anti–PD-1/PD-L1 in Advanced Urothelial Cancer. Eur Urol 2020;77:269–76: Progression and Hyperp

Re: Silke Gillessen, Gerhardt Attard, Tomasz M. Beer, et al. Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. Eur Urol. 2020;77: 508–47 https://doi.org/10.1016/j.eururo.2020.01.01

Re: Lisa Moris, Marcus G. Cumberbatch, Thomas Van den Broeck, et al. Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostate Cancer: An International Multidisciplinary Systematic Review. Eur Urol 2020;77:614–27

Reply to Alireza Ghoreifi and Hooman Djaladat’s Letter to the Editor re: Fredrik Liedberg, Petter Kollberg, Marie Allerbo, et al. Preventing Parastomal Hernia After Ileal Conduit by the Use of a Prophylactic Mesh: A Randomised Study. Eur Urol. In pre

Re: Fredrik Liedberg, Petter Kollberg, Marie Allerbo, et al. Preventing Parastomal Hernia After Ileal Conduit by the Use of a Prophylactic Mesh: A Randomised Study. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.07.033

Re: Beatriz Goulao, Sonya Carnell, Jing Shen, et al. Surgical Treatment for Recurrent Bulbar Urethral Stricture: A Randomised Open-label Superiority Trial of Open Urethroplasty Versus Endoscopic Urethrotomy (the OPEN Trial). Eur Urol 2020;78:572–80

Re: Madhuri Koti, Molly A. Ingersoll, Shilpa Gupta, et al. Sex Differences in Bladder Cancer Immunobiology and Outcomes: A Collaborative Review with Implications for Treatment. Eur Urol Oncol 2020;3:622–30

Re: Russell E.N. Becker, Alexa R. Meyer, Aaron Brant, et al. Clinical Restaging and Tumor Sequencing are Inaccurate Indicators of Response to Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer. Eur Urol. In press. https://doi.org/10.1016/j.e

Re: Hugh Mostafid, Ashish M. Kamat, Siamak Daneshmand, et al. Best Practices to Optimise Quality and Outcomes of Transurethral Resection of Bladder Tumours. Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2020.06.010

Re: Hiten D. Patel, Farzana A. Faisal, Bruce J. Trock, et al. Effect of Pharmacologic Prophylaxis on Venous Thromboembolism After Radical Prostatectomy: The PREVENTER Randomized Clinical Trial. Eur Urol 2020;78:360–368

Re: J. Alfred Witjes, Harman Max Bruins, Richard Cathomas, et al. European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines. Eur Urol 2021;79:82–104: Importance of Standardized Patholo

Re: J. Alfred Witjes, Harman Max Bruins, Richard Cathomas, et al. European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines. Eur Urol 2020;79:82–104

Re: Roman Sosnowski, Hubert Kamecki, Steven Joniau, Jochen Walz, Zachary Klaassen, Joan Palou. Introduction of Telemedicine During the COVID-19 Pandemic: A Challenge for Now, an Opportunity for the Future. Eur Urol. In press. https://doi.org/10.1016/

Re: Mikkel Fode, Christian Fuglesang S. Jensen, Peter B. Østergren. How Should the Medical Community Respond to the Low Quality of Medical Information on Social Media? Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.09.050

Re: Fredrik Liedberg, Petter Kollberg, Marie Allerbo, et al. Preventing Parastomal Hernia After Ileal Conduit by the Use of a Prophylactic Mesh: A Randomised Study. Eur Urol 2020;78:757–63

Corrigendum re “Multicriteria Decision Analysis Applied to the Clinical Use of Pharmacotherapy for Overactive Bladder Symptom Complex” [Eur Urol Focus 2020;6:522–30]

Re: Mathieu Rouanne, Dean F. Bajorin, Raquibul Hannan, et al. Rationale and Outcomes for Neoadjuvant Immunotherapy in Urothelial Carcinoma of the Bladder. Eur Urol Oncol 2020;3:728–38

Corrigendum re “Fibroblast Growth Factor Receptor 3 Alteration Status is Associated with Differential Sensitivity to Platinum-based Chemotherapy in Locally Advanced and Metastatic Urothelial Carcinoma” [Eur Urol 2020;78:907–15]

Corrigendum re “Problems with Numbers in Decision Aids for Prostate-specific Antigen Screening: A Critical Review” [Eur Urol 2021;79:330–3]

Re: Dong K, Shen M, Ju G, et al. Off-clamp Retroperitoneoscopic Tumour Evacuation for Sporadic Renal Angiomyolipomas with High RENAL Nephrometry Scores: A Novel Surgical Technique and Its Outcomes. Eur Urol 2021;79:283-289

Re: Peng Xu, Binshen Chen, Abai Xu, Dan Yuan, Yiming Zhang, Chunxiao Liu. Initial Experience with Intracorporeal Laparoscopic Radical Cystectomy and Detaenial Sigmoid Neobladder Reconstruction. Eur Urol 2021;79:545–51

Re: Cosimo De Nunzio, Benjamin Brucker, Thomas Bschleipfer, et al. Beyond Antimuscarinics: A Review of Pharmacological and Interventional Options for Overactive Bladder Management in Men. Eur Urol 2021;79:492–504

Re: Svetlana Avulova, John C. Cheville, Christine M. Lohse, et al. Grading of Chromophobe Renal Cell Carcinoma: Evidence for a Four-tiered Classification Incorporating Coagulative Tumor Necrosis. Eur Urol 2021;79:225–31: Should Chromophobe Renal Cell

Re: Nicolas Mottet, Roderick C.N. van den Bergh, Erik Briers, et al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer—2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol 2021;79:243–62: Comorbidity Meas

Re: Maria S. Lindgren, Peter Bue, Nessn Azawi, et al. The DaBlaCa-13 Study: Short-term, Intensive Chemoresection Versus Standard Adjuvant Intravesical Instillations in Non–muscle-invasive Bladder Cancer—A Randomized Controlled Trial. Eur Urol 2020;78

Re: Sophie Knipper, Luigi Ascalone, Benjamin Ziegler, et al. Salvage Surgery in Patients with Local Recurrence After Radical Prostatectomy. Eur Urol 2021;79:537–44: Surgical Treatment of Local Recurrence Following Radical Prostatectomy: Reality or Il

Re: Patrick D. McGillivray, Daiki Ueno, Aydin Pooli, et al. Distinguishing Benign Renal Tumors with an Oncocytic Gene Expression (ONEX) Classifier. Eur Urol 2021;79:107–11: Integrating 99mTc-sestamibi and ONEX to Optimize Risk Stratification for Rena